Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals, Inc. notified the market of a proposed sale of 13,050 shares of its common stock through Stifel Nicolaus & Company Inc., with an approximate aggregate market value of $711,418.00. The filing states the shares represent part of outstanding common stock of 159,391,229 shares and lists an approximate sale date of 09/02/2025 on Nasdaq. The filer acquired these shares on 01/04/2021 by exercising options from the issuer and plans to receive cash as payment. The notice reports no securities sold in the past three months for the account and includes the required representation that the seller is not aware of any undisclosed material adverse information.
Form 144 notice for Ionis Pharmaceuticals (IONS) reports a proposed sale of 20,000 shares of common stock through Stifel Nicolaus & Company on 09/02/2025 on Nasdaq with an aggregate market value of $1,018,296. The filing states there are 159,391,229 shares outstanding.
The securities to be sold were acquired as restricted stock units on 01/15/2017 totaling 78,321 shares, with payment noted as cash. The filing also discloses a prior sale by Lynne Parshall of 5,000 shares on 08/06/2025 for gross proceeds of $209,646. The notice includes the standard representation that the seller has no undisclosed material information.
Ionis Pharmaceuticals reported positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG). Across nearly 1,100 patients required to remain on standard-of-care lipid-lowering therapy, olezarsen produced highly statistically significant, placebo-adjusted mean reductions in fasting triglycerides of up to 72% and a highly statistically significant 85% reduction in acute pancreatitis events. Both 80 mg and 50 mg monthly doses met the primary endpoint at six months with strong p-values (p<0.0001), and the company described safety and tolerability as favorable.
Ionis Pharmaceuticals Form 144 notice: A holder intends to sell 1,427 shares of Ionis common stock through Insight Securities on the NYSE. The shares were acquired as compensation from Ionis on 08/22/2025 and the planned sale date is listed as 08/22/2025. The filing reports no shares sold in the past three months by the seller. The filing states the seller represents they have no undisclosed material adverse information about the issuer.
Allene M. Diaz, a director of Ionis Pharmaceuticals (IONS), reported the sale of 1,427 shares of common stock on 08/22/2025 at a weighted-average price of $42.5278 per share, reducing her direct holdings to 18,368 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted May 3, 2023, and the filing notes the shares were sold in multiple transactions at prices ranging $42.30 to $42.75. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported option exercise and share sale transactions on 08/18/2025. He was granted or exercised a non-qualified stock option with a $32.60 exercise price covering 10,000 shares exercisable from 01/03/2023 and expiring 01/02/2032, which increased his direct common stock holdings to 103,466 shares. On the same date, he sold 10,000 shares pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025, for a weighted average price of $43.9776 per share (sales occurred at prices between $43.75 and $44.25). Following the sale, his reported direct common stock ownership was 93,466 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on behalf of Mr. Bennett.
Ionis Pharmaceuticals Form 144 filing summary — This notice reports a proposed sale of 16,000 shares of the issuer's common stock through Stifel Nicolaus & Company, Inc. with an aggregate market value of $703,642.00. The sale is scheduled approximately for 08/18/2025 on Nasdaq. The filing lists prior acquisitions underlying the shares: an option exercise on 01/03/2022 totaling 28,869 shares, restricted stock units granted on 01/15/2017 for 7,537 shares, and restricted stock units on 01/15/2016 for 6,373 shares. The table for sales during the past three months shows Nothing to Report. Several identifying fields (filer CIK/CCC and the named person for whose account the sale is proposed) are not provided in the content.
Ionis Pharmaceuticals director B. Lynne Parshall sold 5,000 shares of Ionis common stock on 08/06/2025 under a pre-established Rule 10b5-1 trading plan adopted May 6, 2025. The filings report two sales: 4,600 shares at a weighted-average price of $41.8685 (individual trade prices ranged from $41.50 to $42.36) and 400 shares at a weighted-average price of $42.6275 (individual trade prices ranged from $42.56 to $42.83). Following the reported transactions, the Form 4 shows beneficial ownership figures of 86,744 shares and 86,344 shares respectively. The reporting person is identified as a director and the sales were executed pursuant to the disclosed trading plan.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
